State Street’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

State Street’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,520	Closed	-$7.51K	–	4795
2023 Q1	$7.51K	Hold	2,520	–	–	﹤0.01%	4755
2022 Q4	$12.6K	Hold	2,520	–	–	﹤0.01%	4782
2022 Q3	$16K	Hold	2,520	–	–	﹤0.01%	4855
2022 Q2	$18K	Sell	2,520 -8,500	-77%	-$77.3K	﹤0.01%	4888
2022 Q1	$163K	Buy	11,020 +260	+2%	+$6.61K	﹤0.01%	4457
2021 Q4	$516K	Buy	10,760 +3	+0%	+$315	﹤0.01%	4011
2021 Q3	$1.57M	Buy	10,757 +1,520	+16%	+$197K	﹤0.01%	3674
2021 Q2	$1.07M	Buy	9,237 +4,327	+88%	+$482K	﹤0.01%	3657
2021 Q1	$473K	Buy	+4,910	New	+$641K	﹤0.01%	3741

Other funds holding LABP

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street's LABP Position: Q2 2023 in Review

State Street sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2023, closing a stake of 2,520 shares — an estimated $7.51K sold.

State Street first reported a position in LABP in Q1 2021 and held it in 9 quarters. The position peaked at $1.57M in Q3 2021. 8 funds tracked by Wall St. Rank hold LABP as of Q2 2023.

State Street reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
State Street sold 2,520 Landos Biopharma, Inc. Common Stock shares in Q2 2023, an estimated $7.51K.
State Street first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
State Street's Landos Biopharma, Inc. Common Stock position peaked at $1.57M in Q3 2021.
8 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.